Overview

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

This will be a randomized, single dose, open-label, three-treatment period crossover study in healthy participants to determine whether 2 test lots of 10-mg capsules that vary by the level of lenvatinib Type-C crystal are bioequivalent to a reference lot of 10-mg capsules.

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Lenvatinib